An alarming and recent 483 highlights FDA’s continued scrutiny of data integrity issues concerning the validation of Laboratory Information Management Systems. The 483 reads:
“Your LIMS computerized system, used for generating official GMP testing results and provided to your clients, is not validated. During the current inspection, I observed the LIMS system used to generate GMP data does not prevent alteration or deletion of data generated.“
When computerized systems aren’t validated, they become a source of risk rather than reliability. Data Integrity failures have direct implications for product quality, regulatory compliance, and patient safety. System validation is a non-negotiable requirement for a sound quality program.
Under 21 CFR Part 11.10 and FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, any electronic system used to support cGMP activities must ensure:
- Data is attributable, legible, contemporaneous, original, and accurate.
- Access is restricted to authorized personnel.
- Audit trails are complete, secure, and tamper-evident.
- The system functions are validated.
In the digital age, your data is only as trustworthy as the system that manages it. If you’re using a LIMS to generate GMP results, validation is a legal and ethical requirement.
